Intellia Therapeutics, Inc.
corporate_fare Company Profile
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for NTLA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for NTLA spans 8-K, 10-Q, 424B5.
Recent high-impact activity:
- Intellia Outlines Lonvo-z Launch Strategy Ahead of March 10, 2027 PDUFA
- Intellia's One-Time CRISPR HAE Therapy Shows Four-Year Durability Ahead of March PDUFA
- Intellia Posts $127.5M Q3 Loss as Cash Burn Accelerates
- FDA Accepts Intellia's BLA for Lonvo-z with Priority Review; PDUFA Date Set for March 10, 2027
- FDA Accepts Intellia's BLA for Lonvo-z with Priority Review, PDUFA Date March 10, 2027
Financial Snapshot
Short Interest & Short Volume
11.05 days to coverFINRA reported short interest of 44,361,762 shares in NTLA as of the October 30, 2026 settlement, a 0.2% decrease from the prior period — about 11.1 days to cover at its recent average daily volume. On November 20, 2026, 52.5% of NTLA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NTLA, detected from its recent SEC filings.
Shelf Renewal Replaces Expiring Registration · Existing ATM Capacity Re-Registered
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →